Skip to main content

Table 1 Characteristics of the IPF and control cohorts

From: Circulating matrix metalloproteinases and tissue metalloproteinase inhibitors in patients with idiopathic pulmonary fibrosis in the multicenter IPF-PRO Registry cohort

Characteristic

IPF (N = 300)

Control (N = 100)

Age (years)

70.0 (65.0, 75.0)

66.0 (63.0, 71.5)

Male

223 (74.3%)

74 (74%)

Race

 White

281 (93.7%)

100 (100%)

 Black or African-American

8 (2.7%)

0 (0%)

 Asian

6 (2.0%)

0 (0%)

 Other

5 (1.7%)

0 (0%)

Ethnicity: Hispanic or Latino

8 (2.7%)

0 (0%)

Smoking

 Past

202 (67.3%)

68 (68%)

 Never

96 (32.0%)

32 (32%)

 Current

2 (0.7%)

0 (0%)

Diagnostic criteriaa

 Definite IPF

220 (73.3%)

–

 Probable IPF

63 (21.0%)

–

 Possible IPF

17 (5.7%)

–

Presence of emphysema on CT

31 (10.3%)

–

Supplemental oxygen use at rest

59 (20.0%)b

–

Pulmonary function measures

 FEV1 (L)

2.2 (1.8, 2.7)

–

 FEV1 (% predicted)

77.4 (68.0, 89.1)

–

 FVC (L)

2.7 (2.2, 3.2)

–

 FVC (% predicted)

69.7 (61.0, 80.2)

–

 FEV1/FVC ratio

74.1 (72.8, 89.6)

–

 DLCO (mL/min/kPa)

12.0 (8.6, 14.7)

–

 DLCO (% predicted)

40.6 (31.7, 49.4)

–

 CPI

53.5 (46.6, 60.5)

–

Antifibrotic drug use

 Nintedanib

56 (18.7%)

0 (0%)

 Pirfenidone

106 (35.3%)

0 (0%)

 Neither

138 (46.0%)

100 (100%)

  1. Values are median (Q1, Q3) or n (%)
  2. CT computed tomography, CPI composite physiologic index, DLCO diffusing capacity of the lungs for carbon monoxide, FEV1 forced expiratory volume in 1 s, FVC forced vital capacity
  3. aDetermined by the investigator according to the 2011 ATS/ERS/JRS/ALAT diagnostic guidelines [15]
  4. bInformation available for 295 patients